Insider Transactions in Q4 2021 at Enanta Pharmaceuticals Inc (ENTA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2021
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,944
-0.28%
|
$169,128
$87.68 P/Share
|
|
Dec 01
2021
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.98%
|
$48,459
$87.68 P/Share
|
|
Dec 01
2021
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.16%
|
$48,459
$87.68 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,523
-4.72%
|
$1,176,501
$87.45 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,523
+13.34%
|
$608,535
$45.99 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-2.5%
|
$73,254
$87.68 P/Share
|
|
Dec 01
2021
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.93%
|
$48,459
$87.68 P/Share
|
|
Nov 19
2021
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,700
+3.53%
|
-
|
|
Nov 19
2021
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+10.73%
|
-
|
|
Nov 19
2021
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+1.97%
|
-
|
|
Nov 19
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+16.77%
|
-
|
|
Nov 19
2021
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+10.21%
|
-
|
|
Nov 19
2021
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+50.0%
|
-
|
|
Nov 19
2021
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+50.0%
|
-
|
|
Nov 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,547
-9.14%
|
$811,495
$85.18 P/Share
|
|
Nov 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,547
+20.74%
|
$458,256
$48.52 P/Share
|
|
Oct 11
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,047
-13.06%
|
$283,290
$70.34 P/Share
|
|
Oct 11
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,047
+11.55%
|
$174,021
$43.46 P/Share
|
|
Oct 08
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,453
-33.3%
|
$941,710
$70.09 P/Share
|
|
Oct 08
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,453
+24.98%
|
$578,479
$43.46 P/Share
|